Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
19 nov. 2014 06h00 HE
|
Melinta Therapeutics, Inc.
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
Phase 1b and Phase 2/3 Studies Will Test Intravenous, Oral Capsule and Oral Suspension...
Cempra to Present at Two Upcoming Investor Conferences
10 nov. 2014 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2014 Financial Results and Provides Corporate Update
29 oct. 2014 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on October 29, 2014
22 oct. 2014 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...